Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 10/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173535 | 1.00 | AR (0.55) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL4182043 | 0.92 | AR (0.54) | ARSRD5A1SRD5A2LMNA | |
| SCHEMBL4182039 | 0.92 | AR (0.54) | ARSRD5A1SRD5A2LMNA | |
| SCHEMBL4184510 | 0.90 | SRD5A1 (0.62) | ARSRD5A1SRD5A2 | |
| SCHEMBL4184512 | 0.90 | SRD5A1 (0.62) | ARSRD5A1SRD5A2 | |
| SCHEMBL4187781 | 0.88 | SRD5A1 (0.61) | ARSRD5A1SRD5A2 | |
| SCHEMBL4187777 | 0.88 | SRD5A1 (0.61) | ARSRD5A1SRD5A2 | |
| SCHEMBL5212632 | 0.87 | AR (0.70) | ARSRD5A1SRD5A2 | |
| SCHEMBL5215007 | 0.87 | AR (0.70) | ARSRD5A1SRD5A2 | |
| SCHEMBL4182230 | 0.87 | SRD5A1 (0.63) | ARSRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2009-03-26 | — | — | US | claimed |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MEISSNER ROBERT S | 2007-04-19 | — | — | US | claimed |
| US-7186838-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| EP-1485095-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003077919-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | claimed |
| US-7625920-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2009-03-26 | — | — | US | disclosed |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MEISSNER ROBERT S | 2007-04-19 | — | — | US | disclosed |
| US-7186838-B2 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | disclosed |
| EP-1485095-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003077919-A1 | FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165039-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | AR 2/4885SRD5A1 8/4885SRD5A2 12/4885 |
| US-20070088042-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | AR 2/4885SRD5A1 8/4885SRD5A2 12/4885 |
| US-20090082320-A1 | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | FSHR, AR, NR5A1 | AR 2/4885SRD5A1 8/4885SRD5A2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.